Next-Generation Cancer Immunotherapy
VitaNova Therapeutics is building a platform to discover and develop cancer-specific immunotherapies designed to transform the treatment of cancer.
Who We Are
VitaNova Therapeutics is a biotechnology company focused on translating breakthrough discoveries in cancer biology into next-generation precision therapies.
Our approach focuses on identifying highly selective tumor antigens that enable the development of next-generation therapies including cellular immunotherapies, antibody-based medicines, and targeted immune engagers.
The company’s scientific foundation is built on decades of leading-edge research in oncology and clinical investigation, with a particular focus on high-risk cancers.
A Platform for Cancer-Specific Therapeutics
VitaNova’s platform is designed to unlock a new class of precision immunotherapies.
The company’s discovery approach enables multiple therapeutic modalities across a growing pipeline of oncology programs.
Cell-Surface Targets
These targets enable powerful immunotherapy approaches including:
CAR-T cell therapies
Antibody-Drug Conjugates (ADC)
T-cell engagers (BiTE)
NK-cell engager therapies
Intracellular Targets
Many of the most important cancer drivers exist inside tumor cells.
VitaNova identifies intracellular oncogenic proteins presented on peptide-HLA complexes, enabling the development of:
TCR-mimic antibodies
TCR-engineered cell therapies
Next-generation cellular immunotherapies
This dramatically expands the universe of druggable cancer targets.
Pipeline
VitaNova is advancing a growing pipeline of cancer-specific therapeutic programs across hematologic and solid tumors.
Initial development programs focus on:
Infant Acute Myeloid Leukemia (AML)
Osteosarcoma
High-risk pediatric malignancies
Additional programs are being developed across broader oncology indications.
Built on World-Leading Cancer Research
VitaNova Therapeutics is being developed based on pioneering research in cancer biology and immunotherapy.
This foundation draws on decades of leading-edge work in oncology and clinical investigation, informing a platform designed to accelerate the development of highly selective therapies for patients with high-risk cancers.V
[ VitaNova Therapeutics Platform ]
[ Cancer-Specific Target Discovery ]
[ Cell Surface Targets ] [ Intracellular Targets ]
CAR-T | ADC | Engagers Peptide-HLA | TCR Mimics | TCR Therapies
[ Cancer Indications ]
AML | Osteosarcoma | Solid Tumors
Let’s Stay in Touch
For questions, collaborations, or scientific inquiries, please get in touch.